Endometrial cancer is the leading gynecologic neoplasm in developed countries and the second most frequent one in developing countries . It most frequently affects postmenopausal women, nonetheless, up to one-quarter of endometrial cancer patients are diagnosed prior to menopause . Fortunately, the vast majority of cases (? 80%) are diagnosed at early stage disease and achieve favorable five-year overall survival (OS) rates close to 90% [3,4]. However, nearly 20% and 70% of patients with early and late stage disease, respectively, experience relapse post primary therapy .